Benzinga | Feb 11, 2021 04:16PM EST

Ultragenyx Pharmaceutical Q4 EPS $(0.37) Beats $(1.16) Estimate, Sales $91.54M Beat $70.54M Estimate

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(1.16) by 68.1 percent. This is a 77.16 percent increase over losses of $(1.62) per share from the same period last year. The company reported quarterly sales of $91.54 million which beat the analyst consensus estimate of $70.54 million by 29.77 percent. This is a 157.19 percent increase over sales of $35.59 million the same period last year.